Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Malerba

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
Biomedicines|July 27, 2022
Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit <i>DUX4</i> ExpressionNgoc Lu-Nguyen, George Dickson, Alberto Malerba, et al.
International Journal of Molecular Sciences|July 13, 2024
Systemic Pharmacotherapeutic Treatment of the ACTA1-MCM/FLExDUX4 Preclinical Mouse Model of FSHDNgoc Lu-Nguyen, Stuart Snowden, Linda Popplewell, et al.
International Journal of Molecular Sciences|June 19, 2024
Targeted Antisense Oligonucleotide-Mediated Skipping of Murine <i>Postn</i> Exon 17 Partially Addresses Fibrosis in D2.<i>mdx</i> MiceJessica Trundle, Ngoc Lu-Nguyen, Alberto Malerba, et al.
Human Gene Therapy|May 28, 2009
Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx miceAlberto Malerba, Francesca C Thorogood, George Dickson, et al.
Methods in Molecular Biology (Clifton, N.J.)|January 4, 2011
Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscleLinda J Popplewell, Ian R Graham, Alberto Malerba, et al.
Expert Opinion on Biological Therapy|June 17, 2009
Gene therapy for muscular dystrophy: current progress and future prospectsCapucine Trollet, Takis Athanasopoulos, Linda Popplewell, et al.
Human Molecular Genetics|May 14, 2021
Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse modelNgoc Lu-Nguyen, Alberto Malerba, Shan Herath, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 7, 2010
Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatmentJagjeet K Kang, Alberto Malerba, Linda Popplewell, et al.
Frontiers in Physiology|March 21, 2020
Inhibition of Myostatin Reduces Collagen Deposition in a Mouse Model of Oculopharyngeal Muscular Dystrophy (OPMD) With Established DiseasePradeep Harish, Leysa Forrest, Shanti Herath, et al.
Human Gene Therapy|January 26, 2022
Improving Molecular and Histopathology in Diaphragm Muscle of the Double Transgenic ACTA1-MCM/FLExDUX4 Mouse Model of FSHD with Systemic Antisense TherapyNgoc Lu-Nguyen, Alberto Malerba, Marina Antoni Pineda, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Biomedicines|July 27, 2022
Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit <i>DUX4</i> ExpressionNgoc Lu-Nguyen, George Dickson, Alberto Malerba, et al.
International Journal of Molecular Sciences|July 13, 2024
Systemic Pharmacotherapeutic Treatment of the ACTA1-MCM/FLExDUX4 Preclinical Mouse Model of FSHDNgoc Lu-Nguyen, Stuart Snowden, Linda Popplewell, et al.
International Journal of Molecular Sciences|June 19, 2024
Targeted Antisense Oligonucleotide-Mediated Skipping of Murine <i>Postn</i> Exon 17 Partially Addresses Fibrosis in D2.<i>mdx</i> MiceJessica Trundle, Ngoc Lu-Nguyen, Alberto Malerba, et al.
Human Gene Therapy|May 28, 2009
Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx miceAlberto Malerba, Francesca C Thorogood, George Dickson, et al.
Methods in Molecular Biology (Clifton, N.J.)|January 4, 2011
Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscleLinda J Popplewell, Ian R Graham, Alberto Malerba, et al.
Expert Opinion on Biological Therapy|June 17, 2009
Gene therapy for muscular dystrophy: current progress and future prospectsCapucine Trollet, Takis Athanasopoulos, Linda Popplewell, et al.
Human Molecular Genetics|May 14, 2021
Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse modelNgoc Lu-Nguyen, Alberto Malerba, Shan Herath, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 7, 2010
Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatmentJagjeet K Kang, Alberto Malerba, Linda Popplewell, et al.
Frontiers in Physiology|March 21, 2020
Inhibition of Myostatin Reduces Collagen Deposition in a Mouse Model of Oculopharyngeal Muscular Dystrophy (OPMD) With Established DiseasePradeep Harish, Leysa Forrest, Shanti Herath, et al.
Human Gene Therapy|January 26, 2022
Improving Molecular and Histopathology in Diaphragm Muscle of the Double Transgenic ACTA1-MCM/FLExDUX4 Mouse Model of FSHD with Systemic Antisense TherapyNgoc Lu-Nguyen, Alberto Malerba, Marina Antoni Pineda, et al.
Pageof 6